Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain
Rev. Soc. Bras. Med. Trop
;
36(2): 201-209, mar.-abr. 2003. ilus, tab, graf
Article
in English
| LILACS
| ID: lil-340897
ABSTRACT
The present investigation was performed to evaluate the susceptibility of seven clones isolated from the highly resistant Colombian strains, prototype of Biodeme Type III. Seven clones previously obtained, showed a phenotypic homogeneity and high similarity with the parental strain. Eight groups of 30 mice were inoculated with one of seven clones or the parental strain; 20 were treated with benznidazole (100mg/kg/day) and 10 were untreated controls. Cure evaluations were done by parasitological and serological tests and PCR. Cure rates varied from 0 percent (null) to 16.7 percent. Correlation between positivity of parasitological and serological tests with positive PCR reached 37 percent. The results demonstrated the high resistance of the clones, suggesting the predominance of a highly resistant principal clone in this strain. The findings apparently indicate that the possibility of cure is minimal for patients infected with this biodeme; a fact that could affect the control of Chagas' disease through treatment of chronically infected people
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Trypanocidal Agents
/
Trypanosoma cruzi
/
Chagas Disease
/
Nitroimidazoles
Limits:
Animals
Country/Region as subject:
South America
/
Colombia
Language:
English
Journal:
Rev. Soc. Bras. Med. Trop
Journal subject:
Tropical Medicine
Year:
2003
Type:
Article
/
Project document
Affiliation country:
Brazil
Institution/Affiliation country:
Fundação Oswaldo Cruz/BR
Similar
MEDLINE
...
LILACS
LIS